Association of high UGT2B17 (> 1.77) versus low (≤ 1.77) mRNA expression with prognostic markers in CLL
| Marker . | N total . | CLL patients with high UGT2B17 (n) . | CLL patients with low UGT2B17 (n) . | P . | OR/HR . | 95% CI . |
|---|---|---|---|---|---|---|
| Binet stage B or C | 239 | 21.8% (119) | 15.0% (120) | .172 | 1.58 | 0.82-3.08 |
| Positive Coombs test | 224 | 8.2% (110) | 1.8% (114) | .026 | 4.99 | 1.05-23.64 |
| High LPL-expression (> 10 fold of healthy donor) | 167 | 60.2% (93) | 29.7% (74) | < .001 | 3.58 | 1.87-6.84 |
| High CD38 expression (> 30% of CD19+ cells) | 219 | 44.1% (111) | 21.3% (108) | < .001 | 3.03 | 1.67-5.48 |
| Cytogenetics | ||||||
| 17p deletion | 227 | 6.9% (116) | 10.8% (111) | .298 | 0.61 | 0.24-1.56 |
| 11q deletion | 227 | 28.4% (116) | 18.0% (111) | .063 | 1.81 | 0.96-3.40 |
| trisomy 12 | 227 | 21.6% (116) | 11.7% (111) | .047 | 2.07 | 1.00-4.29 |
| 13q deletion as sole abnormality | 227 | 18.1% (116) | 35.1% (111) | .004 | 0.41 | 0.22-0.75 |
| 14q aberrations | 227 | 20.9% (116) | 15.3% (111) | .279 | 1.46 | 0.74-2.89 |
| normal caryotype | 227 | 22.4% (116) | 24.3% (111) | .734 | 0.90 | 0.49-1.66 |
| Unmutated IGHV (> 98% sequence homology) | 185 | 59.6% (99) | 24.4% (86) | < .001 | 4.57 | 2.42-8.61 |
| IGHV gene usage | ||||||
| 1-69 | 183 | 21.8% (101) | 6.1% (82) | .004 | 4.21* | 1.50-11.77 |
| 3-21 | 183 | 5.0% (101) | 3.7% (82) | .532 | 1.59* | 0.37-6.94 |
| 3-23 | 183 | 5.9% (101) | 11.0% (82) | .414 | 0.64* | 0.21-1.89 |
| UGT2B17 CNV (percentage +/+)† | 167 | 50.5% (105) | 41.9% (62) | .286 | 1.41 | 0.75-2.66 |
| Median treatment free survival, mo | 239 | 62.6 (81/119)‡ | 154.1 (52/120)‡ | < .001 | 2.25 | 1.58-3.27 |
| Median overall survival, mo | 240 | 152.4 (29/120)‡ | 299.5 (19/120)‡ | .013 | 2.18 | 1.18-4.01 |
| Marker . | N total . | CLL patients with high UGT2B17 (n) . | CLL patients with low UGT2B17 (n) . | P . | OR/HR . | 95% CI . |
|---|---|---|---|---|---|---|
| Binet stage B or C | 239 | 21.8% (119) | 15.0% (120) | .172 | 1.58 | 0.82-3.08 |
| Positive Coombs test | 224 | 8.2% (110) | 1.8% (114) | .026 | 4.99 | 1.05-23.64 |
| High LPL-expression (> 10 fold of healthy donor) | 167 | 60.2% (93) | 29.7% (74) | < .001 | 3.58 | 1.87-6.84 |
| High CD38 expression (> 30% of CD19+ cells) | 219 | 44.1% (111) | 21.3% (108) | < .001 | 3.03 | 1.67-5.48 |
| Cytogenetics | ||||||
| 17p deletion | 227 | 6.9% (116) | 10.8% (111) | .298 | 0.61 | 0.24-1.56 |
| 11q deletion | 227 | 28.4% (116) | 18.0% (111) | .063 | 1.81 | 0.96-3.40 |
| trisomy 12 | 227 | 21.6% (116) | 11.7% (111) | .047 | 2.07 | 1.00-4.29 |
| 13q deletion as sole abnormality | 227 | 18.1% (116) | 35.1% (111) | .004 | 0.41 | 0.22-0.75 |
| 14q aberrations | 227 | 20.9% (116) | 15.3% (111) | .279 | 1.46 | 0.74-2.89 |
| normal caryotype | 227 | 22.4% (116) | 24.3% (111) | .734 | 0.90 | 0.49-1.66 |
| Unmutated IGHV (> 98% sequence homology) | 185 | 59.6% (99) | 24.4% (86) | < .001 | 4.57 | 2.42-8.61 |
| IGHV gene usage | ||||||
| 1-69 | 183 | 21.8% (101) | 6.1% (82) | .004 | 4.21* | 1.50-11.77 |
| 3-21 | 183 | 5.0% (101) | 3.7% (82) | .532 | 1.59* | 0.37-6.94 |
| 3-23 | 183 | 5.9% (101) | 11.0% (82) | .414 | 0.64* | 0.21-1.89 |
| UGT2B17 CNV (percentage +/+)† | 167 | 50.5% (105) | 41.9% (62) | .286 | 1.41 | 0.75-2.66 |
| Median treatment free survival, mo | 239 | 62.6 (81/119)‡ | 154.1 (52/120)‡ | < .001 | 2.25 | 1.58-3.27 |
| Median overall survival, mo | 240 | 152.4 (29/120)‡ | 299.5 (19/120)‡ | .013 | 2.18 | 1.18-4.01 |
Statistically significant associations are shown in bold.
Compared to other, nonlisted, IGHV genes.
Percentage of homozygous (+/+) in relation to all patients with at least one UGT2B17 allele; patients with the −/− null genotype were excluded from this analysis.
N events/total number of patients analyzed.